HOME >> MEDICINE >> NEWS
Cancer drug proves effective in treating sickle cell disease

Researchers at the University of Illinois at Chicago College of Medicine have demonstrated that a drug long used to treat cancer is also effective in combating sickle cell disease.

The drug, called decitabine, works even in patients who don't respond to hydroxyurea, the standard treatment, and appears to produce fewer side effects.

"The results of our study are compelling," said Joseph DeSimone, professor of hematology and oncology and a member of the UIC Cancer Center. "Clearly, decitabine is an effective therapy for patients who do not benefit from the traditional treatment. It is possibly even an improvement, although more studies will have to be done."

The clinical trial was conducted at the University of Illinois Medical Center at Chicago, which houses the area's only clinic specializing in sickle cell disease. Results of the study will appear in the June 1 issue of the scientific journal Blood.

Sickle cell disease is caused by a single mutation in a gene that manufactures hemoglobin, the molecule in red blood cells that delivers oxygen to tissues throughout the body.

The defective form of hemoglobin, called hemoglobin S (for sickle), causes serious health problems. Red blood cells take on a characteristic crescent, or sickle, shape and stick to blood vessel walls.

As a result, the cells cannot squeeze through capillaries. Blood supply is blocked, depriving tissues and organs of oxygen and causing short- and long-term damage. Patients suffer episodes of intense pain, typically in the arms, legs and back, but also in the liver, kidney and abdomen.

In some severe cases, transfusions may be required because the aberrant red blood cells have a much shorter life span than normal red blood cells (10 days vs. 100) and the body can't manufacture enough new red blood cells to keep up, leading to anemia.

Patients may also suffer what is called acute chest syndrome, a particularly serious complication and th
'"/>

Contact: Sharon Butler
sbutler@uic.edu
312-355-2522
University of Illinois at Chicago
17-May-2002


Page: 1 2 3

Related medicine news :

1. Cancer in patients with hepatitis C
2. Olson family donates $1 million to Arizona Cancer Center
3. Cancer vaccines: A two-pronged attack?
4. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
5. ESMO and Imedex announce partnership for the World Congress on Gastrointestinal Cancer
6. UT Southwestern Moncrief Cancer Center is first in Texas to treat patients with TomoTherapy
7. Cancer researchers seek to predict tumor growth
8. UGA professor receives $3 million grant from National Cancer Institute for breast cancer research
9. Cancer patients in Europe unite with doctors
10. Fox Chase Cancer Center researchers identify novel target for detecting ovarian cancer in blood
11. Cancer burden seen even many years after diagnosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... Gilmer, TX (PRWEB) , ... May 04, 2016 ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/4/2016)... ... May 04, 2016 , ... May kicked off with Melanoma Monday , ... Dermatologist Dr. Ellen Turner is encouraging her patients, as well as residents all around ... safety and health now and in the future. , The dermatology-specific awareness month ends ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... Dr. ... offering wisdom tooth removal surgery at their office. Wisdom tooth removal, a common dental ... not always problematic, they often are improperly erupted, resulting in risks of complications. By ...
(Date:5/4/2016)... ... 2016 , ... Nordic Naturals announces another breakthrough innovation—Omega Curcumin, ... synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 mg concentrated ... and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays a distinct ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Francesca Loparco, Co-Founder ... her life forever with a same-day LASIK procedure at Christenbury Eye Center. ... Dr. Jonathan Christenbury performed her surgery the same day as her in-office consultation and ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016 ... INTP), a clinical-stage biopharmaceutical company, today announced the appointment ... and Regulatory Affairs. "Ms. Strauss-Levy has 15 ... and has established an outstanding track record, having supported ... and regulatory approval processes in the United ...
(Date:5/3/2016)... , May 3, 2016 ... bekannt, dass sie einen entscheidenden Meilenstein durch ... Ein Aufruf zum Handeln, um Patientenresultate  bei ... trägt zu Fortschritten im Verständnis der Hepatischen ... ein Bewusstsein für Hepatische Enzephalopathie in der ...
(Date:5/2/2016)... May 2, 2016  Deerfield announced today it ... Graybug Vision, Inc. Graybug Vision is an early ... may transform care for ocular diseases including wet ... technology was first developed at Johns Hopkins University ... venture. Graybug Vision is developing ...
Breaking Medicine Technology:
Cached News: